# eXalt3 (NCT02767804)

> eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients

No report yet. It can be ordered.

- Drugs tested: ensartinib
- Indication: ALK-positive non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02767804
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Xcovery Holdings, Inc.
- Conditions: Non-small Cell Lung Cancer
- Interventions: X-396 (ensartinib); crizotinib
- Enrollment: 290
- Primary outcome: Progression-free survival (PFS)

## Indexed commentary on eXalt3 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 54 posts on X
- 6 podcast episodes
- 5 YouTube videos

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=exalt3-nct02767804

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02767804", "email": "<work email>"}; the inbox owner confirms by the emailed link.
